SynthesisFrontiers in medicine2026
Research progress and trends of gut microbiota and lung injury: a bibliometric and visualization analysis based on two databases (2015-2026).
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota has emerged as an important regulator of lung injury, but the field's research structure, hotspots and emerging directions remain unclear. This study mapped the development and knowledge landscape of gut microbiota and lung injury research. Methods: Publications indexed in the Web of Science Core Collection (WoSCC) and Scopus from 2015 to May 2026 were analyzed using VOSviewer, CiteSpace and Bibliometrix. Results: Publication output increased markedly, particularly after 2019, with China and Fudan University leading national and institutional contributions, respectively. Conclusion: Major research themes included microbiota-mediated regulation of pulmonary immunity, the protective effects of short-chain fatty acids (SCFAs), and microbiota-targeted interventions involving probiotics and traditional Chinese medicine (TCM). The field remains dominated by mechanistic and preclinical studies, underscoring the need for standardized methods and clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.